الفهرس 
Review of LiteratureOnly 14 pages are availabe for public view
 |  | from | 101 |  |  |
| | | from | 101 | | |
Abstract
1) Larger sample size is needed in future studies to be more representative.
2) Prospective study has to be done to assess serum complement level as a base line and at regular intervals after starting every antiepileptic drug.
3) Study of different immune parameters(such as immunoglobulins and cytokines) in idiopathic childhood epilepsy patients on different antiepileptic drugs.
SUMMARY
E
pilepsy is one of the most common medical conditions that affect infants and children. Epilepsy impacts children and their families in many different ways, affecting cognition, behavior, and socioeconomic status. Uncontrolled epilepsy and the conditions that cause seizures leave indelible changes that can affect a child for life and even increase the risk of sudden death.
In spite of different available antiepileptic drugs, a significant number of epileptic patients remain resistant to treatment. Recently, many studies highlighted the role of the immune system and the complement pathway in the pathogenesis of epilepsy.
Targeting brain inflammation may represent a novel therapeutic strategy for epilepsy, consistent with efforts to shift focus away from the symptomatic control of seizures to treatments that better target the underlying pathological mechanisms.
This is a case control cross-sectional study, conducted in Ain Shams University hospitals, in which 50 child and adolescent epileptic patients and 50 controls were included.
All patients were subjected to extensive history taking, including, demographic data: age and gender. Clinical data: past medical history, age of onset of disease. Medication received, type of fits, and type of epilepsy. Investigation data: EEG and MRI. We assessed serum complement component C3 in patients and control groups.
The study showed a statistically significant reduction in C3 serum level in cases compared to controls. However, there was no significant difference in serum complement level between patients on different antiepileptic drugs or between patients with controlled and uncontrolled seizures